Immunic Doubles Down On Lead Asset With New Data In Ulcerative Colitis
The company is emphasizing development of vidofludimus calcium in multiple indications and deprioritizing izumerogant, an asset the company was developing in psoriasis and prostate cancer.
You may also be interested in...
At Digestive Disease Week, Celltrion will seek to strengthen its hold on the IBD market, Ironwood hopes to expand Linzess into pediatric functional constipation, and competitors will showcase competing short bowel syndrome treatment and colorectal cancer companion diagnostics.
The ulcerative colitis and Crohn’s disease landscapes may shift soon but new drugs will compete with entrenched blockbusters, including Humira, Stelara and Entyvio, with biosimilars on the way.
Without disclosing full Phase Ib data, the company reported a higher-than-expected placebo response versus IMU-935. With its second setback this year Immunic has a long path to meaningful data.